Skip to main
  1. Stocks
  2. OnKure Therapeutics Inc
  3. Forecast
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics is well positioned by a differentiated structure-based platform that is advancing OKI-345 and OKI-355 as selective inhibitors of mutant PI3Kα while sparing wild-type PI3Kα, a design that could improve efficacy and tolerability versus older targeted agents. The company’s recent quarterly update and KOL event reinforced the scientific rationale for broader hotspot coverage, deeper target inhibition, and a wider therapeutic index, while preclinical data showed strong cellular selectivity across PI3KαH1047R, PI3KαE545K, and PI3KαE542K. Financially, OnKure ended 2Q with $176M in cash, which should fund operations into 2029, supporting continued development through anticipated IND submissions in 1H27 and expanding its clinical and commercial opportunity in PI3Kα-driven cancers.

Bears say

OnKure Therapeutics is a clinical-stage biopharmaceutical company with no operating revenue shown in the provided data, and the “Collaboration revenue, related party” line reported as a dash underscores the lack of meaningful commercial traction. Its business remains concentrated in a single clinical research segment and heavily dependent on unproven precision-medicine programs, especially the PI3Kα-focused OKI-219, which increases binary clinical and development risk. With no evidence here of diversified revenue streams, approved products, or scale, the fundamental story appears reliant on future trial success rather than current financial performance.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

OKUR Analyst Forecast & Price Prediction

Get the latest OKUR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OKUR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Oct 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


OKUR Analyst Forecast & Price Prediction

Get the latest OKUR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OKUR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OKUR stock data and trends